1. ABPH BVZA Hospital Pharmacist of Belgium
Belgium is finally making transition in biosimilars’ use (epoetin, filgrastim, infliximab)
7/01/2016: gentlemen’s agreement between the Secretary of Health, professional organizations of relevant prescribers, hospitals, hospital pharmacists and the pharmaceutical industry
Call from the Secretary of Health to use more biosimilars
Enhancement of competition in the market of biologicals should reduce prices  more money for research in innovative therapy
Working group to evaluate biosimilars’ use in hospitals (surveys)
Full switch is accepted
10% less reimbursement on biologicals

2. ABPH BVZA Hospital Pharmacist of Belgium
stimulated by Government – 12 pilot projects
OPAT (Outpatient Parenteral Antimicrobial Therapy)
limited implementation due to practical and legal barriers (cost for patient, time consuming, medications not always available in public pharmacies)
goal is a national OPAT guideline
Oncological Therapy at Home
multidisciplinary teams around the patient
hospital pharmacist involved in development of protocols (medication handling), guidelines, information leaflets for the patient and caregivers, delivery of the hospital medication, in-hospital preparation of IV medication